|
Accueil > Actualité
AstraZeneca: Lynparza in China for ovarian cancer
(CercleFinance.com) - On Thursday AstraZeneca announced that China has approved the marketing of Lynparza, the drug it markets with the US group Merck, for the treatment of ovarian cancer, the third most common gynaecological cancer in the country.
The biopharmaceutical group says that the green light from the Chinese authorities concerns first-line maintenance treatment of the disease, in combination with Roche's Avastin, in patients known as "with HRD". AstraZeneca points out that the five-year survival rate for ovarian cancer is barely 39%, a phenomenon it explains by the fact that over 70% of patients are diagnosed in the late stages of the disease. Copyright (c) 2022 CercleFinance.com. All rights reserved. |
19/04/2024 17:30
Danoneen hausse après deux analyses positives 19/04/2024 16:35 TotalEnergiespartenariat avec OK Petroleum aux USA 19/04/2024 16:29 BAE Systemsmodernise une usine de munitions 19/04/2024 16:15 Netflixle titre trébuche après une publication contrastée 19/04/2024 16:09 Bayersigne un contrat de fourniture d'énergie renouvelables 19/04/2024 15:53 L'Oréalentouré après ses ventes trimestrielles Tous les articles sociétés |
